AI stocks benefit from Trump-era tariffs, while Novavax released data showing its flu vaccine outperformed FLUZONE-HD.
2 reports, 1 independent
Updated Jul 13
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AI stocks benefit from Trump-era tariffs, while Novavax released data showing its flu vaccine outperformed FLUZONE-HD.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Novavax vaccine data shows strong immunogenicity, alongside AI stock gains from Trump tariffs.1 source
Novavax faces market headwinds due to policy risks and product concentration, leading to analyst sell ratings.1 source
Keep exploring
The entities involved
-
Novavax
company in Gaithersburg, Maryland
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
Coverage
Newest first; wire copies grouped- Insider MonkeyBTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax
- Insider MonkeyCiti Initiates Coverage of Novavax (NVAX) With a Sell Rating Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated coverage of Nov